Nimodipine versus terfenadine in the treatment of physical stimulus-induced urticaria

P. D. Pigatto, M. Fumagalli, A. Bigardi, G. Altomare, A. F. Finzi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Basophil and mastocyte degranulation is calcium-dependent. Calcium-antagonists can inhibit synthesis of and release in vitro some mediators in various types of cells. Both immunologically stimulated and non-immunologically stimulated release of material from basophils isolated from normal and allergic subjects can be antagonized by calcium blockers. The present study was aimed at testing the therapeutic effects and side effects of nimodipine therapy, a new dihydropyridine anti-calcium derivative for physical stimulus-induced urticaria, in comparison with a standard H1-antihistamine therapy. The study was done in 32 outpatients who had physical stimulus-induced urticaria: 20 patients received nimodipine three times a day in a daily dose of 180 mg, 12 patients were treated with terfenadine in a dose of 120 mg. In the majority of patients treated with both nimodipine and terfenadine, satisfactory clinical results were obtained after 3 weeks of therapy. There were, however, significant (P

Original languageEnglish
Pages (from-to)71-74
Number of pages4
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume45
Issue number1
Publication statusPublished - 1990

Fingerprint

Terfenadine
Nimodipine
Urticaria
Calcium
Basophils
Histamine Antagonists
Therapeutic Uses
Therapeutics
Outpatients

Keywords

  • Calcium-antagonists
  • nimodipine
  • physical urticaria
  • terfenadine

ASJC Scopus subject areas

  • Immunology

Cite this

Nimodipine versus terfenadine in the treatment of physical stimulus-induced urticaria. / Pigatto, P. D.; Fumagalli, M.; Bigardi, A.; Altomare, G.; Finzi, A. F.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 45, No. 1, 1990, p. 71-74.

Research output: Contribution to journalArticle

@article{77be560d5e6b4410908cb7279dba6875,
title = "Nimodipine versus terfenadine in the treatment of physical stimulus-induced urticaria",
abstract = "Basophil and mastocyte degranulation is calcium-dependent. Calcium-antagonists can inhibit synthesis of and release in vitro some mediators in various types of cells. Both immunologically stimulated and non-immunologically stimulated release of material from basophils isolated from normal and allergic subjects can be antagonized by calcium blockers. The present study was aimed at testing the therapeutic effects and side effects of nimodipine therapy, a new dihydropyridine anti-calcium derivative for physical stimulus-induced urticaria, in comparison with a standard H1-antihistamine therapy. The study was done in 32 outpatients who had physical stimulus-induced urticaria: 20 patients received nimodipine three times a day in a daily dose of 180 mg, 12 patients were treated with terfenadine in a dose of 120 mg. In the majority of patients treated with both nimodipine and terfenadine, satisfactory clinical results were obtained after 3 weeks of therapy. There were, however, significant (P",
keywords = "Calcium-antagonists, nimodipine, physical urticaria, terfenadine",
author = "Pigatto, {P. D.} and M. Fumagalli and A. Bigardi and G. Altomare and Finzi, {A. F.}",
year = "1990",
language = "English",
volume = "45",
pages = "71--74",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Nimodipine versus terfenadine in the treatment of physical stimulus-induced urticaria

AU - Pigatto, P. D.

AU - Fumagalli, M.

AU - Bigardi, A.

AU - Altomare, G.

AU - Finzi, A. F.

PY - 1990

Y1 - 1990

N2 - Basophil and mastocyte degranulation is calcium-dependent. Calcium-antagonists can inhibit synthesis of and release in vitro some mediators in various types of cells. Both immunologically stimulated and non-immunologically stimulated release of material from basophils isolated from normal and allergic subjects can be antagonized by calcium blockers. The present study was aimed at testing the therapeutic effects and side effects of nimodipine therapy, a new dihydropyridine anti-calcium derivative for physical stimulus-induced urticaria, in comparison with a standard H1-antihistamine therapy. The study was done in 32 outpatients who had physical stimulus-induced urticaria: 20 patients received nimodipine three times a day in a daily dose of 180 mg, 12 patients were treated with terfenadine in a dose of 120 mg. In the majority of patients treated with both nimodipine and terfenadine, satisfactory clinical results were obtained after 3 weeks of therapy. There were, however, significant (P

AB - Basophil and mastocyte degranulation is calcium-dependent. Calcium-antagonists can inhibit synthesis of and release in vitro some mediators in various types of cells. Both immunologically stimulated and non-immunologically stimulated release of material from basophils isolated from normal and allergic subjects can be antagonized by calcium blockers. The present study was aimed at testing the therapeutic effects and side effects of nimodipine therapy, a new dihydropyridine anti-calcium derivative for physical stimulus-induced urticaria, in comparison with a standard H1-antihistamine therapy. The study was done in 32 outpatients who had physical stimulus-induced urticaria: 20 patients received nimodipine three times a day in a daily dose of 180 mg, 12 patients were treated with terfenadine in a dose of 120 mg. In the majority of patients treated with both nimodipine and terfenadine, satisfactory clinical results were obtained after 3 weeks of therapy. There were, however, significant (P

KW - Calcium-antagonists

KW - nimodipine

KW - physical urticaria

KW - terfenadine

UR - http://www.scopus.com/inward/record.url?scp=0025169701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025169701&partnerID=8YFLogxK

M3 - Article

C2 - 1968727

AN - SCOPUS:0025169701

VL - 45

SP - 71

EP - 74

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 1

ER -